

DND*i*

Drugs for Neglected Diseases *initiative*



ASTMH 2018

AMERICAN SOCIETY
OF TROPICAL
MEDICINE & HYGIENE

**OCTOBER 28 –
NOVEMBER 1, 2018**

SHERATON NEW
ORLEANS AND
NEW ORLEANS
MARRIOTT,
NEW ORLEANS,
LOUISIANA USA

Drugs for Neglected Diseases *initiative*

15 Chemin Louis-Dunant
1202 Geneva

Telephone: +41 22 906 9230

Email: dndi@dndi.org

**Drugs for Neglected Diseases *initiative*
North America**

40 Rector Street, 16th Floor,
New York, NY 10006

Telephone: +1 646 215 7076

Email: dndina@dndi.org

 [@dndi.org](https://www.facebook.com/dndi.org)  [@DNDi](https://twitter.com/DNDi)  [@dndi](https://www.linkedin.com/company/dndi)

 [@drugsforneglecteddiseases](https://www.instagram.com/drugsforneglecteddiseases)

www.dndi.org

MONDAY, OCTOBER 29TH

ORAL PRESENTATION

The burden of skin disease and eye disease due to onchocerciasis in Africa for 2015 and 2025

Session 2 - Filariasis: Epidemiology and control I

DNDi author(s): Belén Pedrique, *Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland*



8:30AM – 8:45AM



Sheraton – Waterbury
(2nd Floor)



POSTER PRESENTATION

The Chagas disease study landscape: Preliminary analysis of a systematic review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform

Session A - 573

DNDi author(s): Eric Chatelain, *DNDi, Geneva, Switzerland*

Fabiana Barreira, Sergio Sosa Estani, *DNDi Latin America, Rio de Janeiro, Brazil*



12:00PM – 1:45PM



Marriott –
Grand Ballroom
(3rd Floor)

POSTER PRESENTATION

A single-center, first-in-human, randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety, tolerability and pharmacokinetics of escalating single doses of emodepside (BAY44-4400) in healthy male subjects

Session A - 534

DNDi author(s): Jean Yves A. Gillon, Karen Dequatre Cheeseman, Sophie Delhomme, Claudia Peña Rossi, Frederic Monnot, Nathalie Strub-Wourgaft, Rob Don, DNDi, Geneva, Switzerland



12:00PM – 1:45PM



Marriott –
Grand Ballroom
(3rd Floor)

POSTER PRESENTATION

Capacity building platform for clinical and operational research on Human African trypanosomiasis

Session A - 567

DNDi author(s): Florent Mbo Kuikumbi, DNDi, Kinshasa, Democratic Republic of Congo

Olaf Valverde, DNDi, Geneva, Switzerland



12:00PM – 1:45PM



Marriott –
Grand Ballroom
(3rd Floor)

ORAL PRESENTATION

Novel 3-dimensional optical scanning in the assessment of patients with mycetoma

Session 28 - Clinical tropical medicine I

DNDi author(s): Eduard E. Zijlstra, DNDi, Geneva, Switzerland



3:00PM – 3:15PM



Sheraton – Rhythms
(2nd Floor)

SOCIAL MEDIA

DNDi is sharing stories of people affected by neglected diseases and the researchers, scientists, and health workers who strive to develop better treatments.

Follow us on social media to join the conversation, and share your story with #IamTropMed



@dndi.org



@DNDi



@dndi



@drugsforneglecteddiseases

SYMPOSIUM

From R&D to access for sleeping sickness elimination: Innovative public-private partnerships for new tools

Co-Chairs: Victor Kande Betu Kumeso, *NTD Director, Ministry of Health, Kinshasa, Democratic Republic of Congo*

Luc Kuykens, *Senior Vice-President Global Health Programs, Sanofi, Gentilly, France*

Bernard Pécoul, *Executive Director, DNDi*

Session introduction: Victor Kande Betu Kumeso, *NTD Director, Ministry of Health, Kinshasa, Democratic Republic of Congo*

Discussion facilitation: Luc Kuykens, *Senior Vice President Global Health Programs, Sanofi, Gentilly, France*

Bernard Pécoul, *Executive Director, DNDi*

An alternative model for drug development:

The story of fexinidazole, Nathalie Strub-Wourgaft, *Director of Neglected Tropical Diseases, DNDi, Geneva, Switzerland*

Working in partnership for sleeping sickness elimination: Using new technologies, Florent Mbo Kuikumbi, *HAT Platform Coordinator, DNDi, Kinshasa, Democratic Republic of Congo*

Finding every last case: The role of diagnostics in HAT elimination, Veerle Lejon, *National Reference Centre for Parasitology, Research Director, Institut de Recherche pour le Développement, Montpellier, France*

Importance of the development of an oral treatment for sleeping sickness through public-private partnership, Luc Kuykens, *Senior Vice-President Global Health Programs, Sanofi, Gentilly, France*

Striving towards HAT elimination in South Sudan: An operational perspective, Laurence Flevaud, *Operational Centre Barcelona-Athens, Médecins Sans Frontières, Barcelona, Spain*

Monitoring HAT elimination: Plans for validation, Gerardo Priotto, *Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland*



Sponsored by
Sanofi & DNDi



CATERED EVENT



7:15PM – 9:15PM



Sheraton – Waterbury
(2nd Floor)



TUESDAY, OCTOBER 30TH

POSTER PRESENTATION

Prioritizing pathogens to support diagnostic product development for febrile illness management: A novel yet pragmatic approach

Session B - 1225

DNDi author(s): Isabela Ribeiro, *DNDi*, Geneva, Switzerland



12:00PM – 1:45PM



Marriott – Grand Ballroom (3rd Floor)

POSTER PRESENTATION

Evaluation of point-of-care tests for visceral leishmaniasis diagnosis in Kenya

Session B - 1271

DNDi author(s): Monique Wasunna, *DNDi Africa*, Nairobi, Kenya



12:00PM – 1:45PM



Marriott – Grand Ballroom (3rd Floor)

6

VISIT US AT BOOTH #318

DNDi

Drugs for Neglected Diseases Initiative

SYMPOSIUM

Overcoming challenges in screening and diagnosis of Chagas disease

Symposium Organizer: Sergio Sosa Estani, *DNDi Latin America, Rio de Janeiro, Brazil*

Co-Chair: Colin Forsyth, *DNDi North America, New York, NY, United States*

Serological diagnostic and Trypanosoma cruzi diversity, Claudia Herrera, *Tulane University, New Orleans, LA, United States*

Latest Developments in Biomarkers Research, Eric Chatelain, *DNDi, Geneva, Switzerland*

Community-based screening of Chagas disease in the USA: Boston's Strong Hearts Program, Julia Koehler, *Boston Children's Hospital, Boston, MA, United States*

Implementation of a simplified diagnostic algorithm in an endemic area of Colombia, Colin J. Forsyth, *DNDi North America, New York, NY, United States*



1:45PM – 3:30PM



Sheraton – Waterbury
(2nd Floor)



WEDNESDAY, OCTOBER 31ST

ORAL PRESENTATION

Pharmacokinetic-pharmacodynamic assessment of the safety of fexinidazole for the treatment of Human African trypanosomiasis

Session 109 - Kinetoplastida: Diagnosis, treatment and vaccine development

DNDi author(s): Nathalie Strub-Wourgraff, Antoine Tarral
DNDi, Geneva, Switzerland



8:15AM – 8:30AM



Sheraton – Rodrigue Gallery (1st Floor)

ORAL PRESENTATION

Modeling and simulations of fexinidazole treatment regimen for human African *Trypanosoma brucei gambiense* trypanosomiasis (g-HAT) and their successful clinical application in adult and child patients

Session 109 - Kinetoplastida: Diagnosis, treatment and vaccine development

DNDi author(s): Antoine Tarral, DNDi, Geneva, Switzerland



9:30AM – 9:45AM



Sheraton – Rodrigue Gallery (1st Floor)

POSTER PRESENTATION

Determination of fexinidazole effect on QTc in healthy volunteers and human African *Trypanosoma brucei gambiense* trypanosomiasis (g-HAT) patients using concentration-response modelling

Session C - LB-5526

DNDi author(s): Antoine Tarral, DNDi, Geneva, Switzerland



12:00PM – 1:45PM



Marriott-Grand Ballroom (3rd Floor)

POSTER PRESENTATION

Sequential versus classical designs for early phase drug trials against visceral leishmaniasis

Session C - LB-5527

DNDi author(s): Fabiana Alves, Manica Balasegaram, Séverine Blesson,
DNDi, Geneva, Switzerland

Raymond Omollo, Monique Wasunna
DNDi Africa, Nairobi, Kenya



12:00PM – 1:45PM



Marriott-Grand Ballroom (3rd Floor)

THURSDAY, NOVEMBER 1ST

ORAL PRESENTATION

Oxfendazole treatment has a macrofilaricidal efficacy against the filarial nematode *Litomosoides sigmodontis* *in vivo* and inhibits *Onchocerca gutturosa* adult worm motility *in vitro*

Session 172 – Filariasis: Clinical

DNDi author(s): Ivan Scandale, DNDi, Geneva, Switzerland



10:30AM – 10:45AM



Sheraton – Rodrigue
Gallery (1st Floor)



DNDi

Drugs for Neglected Diseases *initiative*

BOOTH #318



NTD VIRTUAL REALITY FLMS

We'll be showing films from the HuffPost "Out of Sight" series on sleeping sickness and river blindness. The sleeping sickness film was shot at DNDi clinical sites in the Democratic Republic of Congo, and follows the trip of one of our doctors to develop new treatments. The river blindness film was also shot in Congo (and in Nigeria), and deals with the challenges and successes of eliminating this disease. challenges of and progress toward eliminating three of those diseases.

Watch at
our booth!



SOCIAL MEDIA

DNDi is sharing stories of people affected by neglected diseases and the researchers, scientists, and health workers who strive to develop better treatments.

Follow us on social media to join the conversation, and share your story with #IamTropMed

 @dndi.org  @DNDi  @dndi
 @drugsforneglecteddiseases

Photo credits: Neil Brandvold/DNDi,
Xavier Vahad/DNDi, Angela Boatwright/DNDi

DNDi

Drugs for Neglected Diseases *initiative*



www.dndi.org